Eisai

5 results

Biogen said more data had become available after the two aducanumab studies were discontinued, resulting in a new analysis that showed one of the trials met the main goal. Photograph: Reuters
Alzheimer’s drug hopes see Biogen shares surge 27%

Biogen revived plans on Tuesday to seek US approval for Alzheimer’s treatment aducanumab, surprising investors and saying data from more patients in t(...)

US tariffs on Chinese goods took effect on Friday. Photograph: David Paul Morris/Bloomberg
Trade concerns fail to halt modest market gains

Global markets shrugged off worries over global trade on Friday after US tariffs on Chinese goods took effect. The escalating trade dispute between (...)

US tariffs on Chinese goods took affect on Friday. Photograph: David Paul Morris/Bloomberg
Trade concerns fail to halt modest market gains

Global markets shrugged off worried over global trade on Friday after US tariffs on Chinese goods took effect. The escalating trade dispute between (...)

The rally has been driven by many factors, including hopes of higher shareholder returns, a rise in corporate earnings, a recovery in domestic consumption and more share buying
Nikkei tops 20,000 for the first time in 15 years

Japan’s Nikkei share average topped the psychological 20,000-point mark on Friday for the first time in 15 years on hopes of stronger corporate earnin(...)

Scott McCauley, associate scientist at the Gilead Sciences, makes human proteins at the Gilead laboratory in Foster City, California. Photograph: David Paul Morris/Bloomberg
Counting the cost of cancer as drug rationing introduced

Anne Strange was too ill to dance at the evening reception when her daughter, Debbie, married in November but just being there was enough. The 63-year(...)